3 citations
,
January 2019 in “Indian Journal of Drugs in Dermatology”
This study reports two cases of PRIDEcomplex in nonsmall cell lung cancer patients treated with erlotinib and gefitinib, highlighting cutaneous reactions like papulopustules and paronychia.
This case report describes the management of PRIDEcomplex, a skin and hair condition associated with EGFR inhibitor treatment like cetuximab, emphasizing that it does not require stopping the medication.
43 citations
,
January 2014 in “Indian Journal of Dermatology”
This study reported that EGFR inhibitor therapy in lung and head/neck cancer patients was associated with acneiform eruptions and severe skin dryness, which rarely necessitate discontinuation of treatment and can be managed symptomatically.
June 2026 in “Indian Journal of Postgraduate Dermatology”
In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.
People are discussing the affordability and effectiveness of Indian generic medications for hair loss, specifically oral dutasteride and minoxidil. They mention brands like Dr. Reddy's, Cipla, and KLM, and discuss payment challenges when purchasing from India.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
Finasteride prices in Canada vary, with Costco offering lower prices compared to smaller pharmacies, and no membership is needed to access their pharmacy. Users discuss the cost-effectiveness of oral versus topical treatments, with some preferring oral minoxidil and finasteride due to fewer side effects.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.